Nuvation Bio Stock Surged 160%, Here’s Why
Nuvation Bio (NUVB) stock soared 161%, powered by an 86% revenue jump and a 41% rise in its valuation multiple—fueled by a strong Q3 earnings beat and breakthrough IBTROZI milestones, from Japan approval to promising data and fresh Phase 3 trials. What’s next for this momentum? Keep reading.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 8212025 | 11192025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.7 | 7.2 | 160.9% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 14.4 | 26.7 | 86.3% |
| P/S Multiple | 65.0 | 91.5 | 40.7% |
| Shares Outstanding (Mil) | 340.7 | 342.4 | -0.5% |
| Cumulative Contribution | 160.9% |
So what is happening here? The stock surged 161%, driven by an 86% revenue increase and a 41% boost in its P/S multiple. These shifts set the stage for the key events and updates that follow.
Here Is Why Nuvation Bio Stock Moved
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
- Q3 2025 Earnings Beat: Nuvation Bio beat Q3 2025 EPS and revenue estimates, reporting -$0.16 EPS and $13.12M revenue.
- IBTROZI Launch Success: Strong Q3 2025 IBTROZI sales, $7.7M net product revenue and 204 new patients.
- Japan IBTROZI Approval: IBTROZI approved in Japan on Sept 19, 2025; $25M milestone expected in Q4 2025.
- Positive IBTROZI Data: New data from TRUST-I and TRUST-II studies showed sustained durability of responses for IBTROZI.
- New Phase 3 Enrollment: First patient enrolled in TRUST-IV Phase 3 study for IBTROZI on Sept 30, 2025.
Our Current Assesment Of NUVB Stock
Opinion: We currently find NUVB stock relatively expensive. Why so? Have a look at the full story. Read Buy or Sell NUVB Stock to see what drives our current opinion.
Risk: A solid way to gauge risk for NUVB is by checking its past drawdowns during major market shocks. It fell about 14% during the Covid pandemic, which isn’t too bad. But the inflation shock hit it much harder, with a drop close to 93%. Even with strong fundamentals, these numbers show that NUVB isn’t immune when the market turns ugly. Good setup or not, steep declines can still happen when volatility spikes.
NUVB stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.